Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms

The goal of this clinical trial is to test the safety and preliminary efficacy of a new drug, KLS-1, in adults with different types of solid tumors and chronic lymphocytic leukemia (CLL). The main questions it aims to answer are: * To define Dose Limiting Toxicities (DLT) and maximum tolerated dose (MTD) of KLS-1 * To select the recommended Phase II Dose (P2D) of KLS-1 * To determine the single dose and multiple dose PK profile following IV administration of KLS-1 * What is the safest and most effective dose of KLS-1? * Does KLS-1 show anti-tumor activity in patients? * To evaluate preliminar

Trial Details

NCT ID
NCT06506643
Phase
PHASE1 / PHASE2
Sponsor
Vector Vitale LLC
Status
RECRUITING
Cancer Type
Chronic Lymphocytic (CLL) Leukemia
Interventions
  • Zinc-64 Aspartate
Locations (sample)
  • Kropyvnytskyi, Ukraine|48.50834,32.26618
  • Kyiv, Ukraine|50.45466,30.5238

Key Eligibility Criteria

  • Phase I and Phase II - solid tumors cohorts
  • Adult (male or female) aged ≥18 years.
  • Signed informed consent prior to any study-specific procedures.
  • Patients who are willing to make themselves available for the duration of the study and are willing to follow study procedures.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Chronic Lymphocytic (CLL) Leukemia Trials on Trialify →